Refine by
Treating Prostate Cancer Suppliers & Manufacturers
14 companies found
based inVaulx-en-Velin, FRANCE
Global leader in therapeutic ultrasound and present in the market for more than 35 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. EDAP TMS ...
Focal treatment strategy for Prostate Cancer (PCa) is playing a growing role in today's surgical practice. By combining the latest imaging and treatment technologies, Focal One® brings the answer to current requirements for ideal focal therapy: ...
based inToronto, ONTARIO (CANADA)
Focal Healthcare is a world-class medical device company dedicated to improving the physician and patient experience from prostate cancer diagnosis to treatment. Throughout his career, Chicuong realized that there were many inefficiencies, ...
based inStafford, VIRGINIA (USA)
We are Hyper-accelerate drug and medical device development. Computational models and AI allow to dramatically accelerate the development of new drugs and medical devices, to reduce, refine and replace tests on animals and clinical trials, to ...
PCa GnRH Agonists Simulator enables simulations of clinical trials on a virtual population of prostate cancer patients being treated with a GnRH agonist ...
based inBellaire, TEXAS (USA)
C4 Imaging develops innovative medical devices that enable clinicians to personalize patient care through accurate image-guided procedures. The company’s core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that has ...
“Permanent prostate brachytherapy dosimetry based only on MRI using positive contrast MRI markers [Sirius®] is feasible, accurate, and reduces the uncertainties arising from CT-MRI fusion abating the need for postimplant multimodality ...
based inArnhem, NETHERLANDS
Soteria Medical B.V. is a Spin Off from Radboudumc in Nijmegen, The Netherlands. Many years of development and clinical research have resulted in a new approach to perform MRI guided interventions by utilizing a robotic device, which is fully ...
Prostate cancer is the most common cancer, other than non-melanoma skin cancer, and the second leading cause of cancer-related death in men in the United States. Prostate cancer incidence rates rose dramatically in the late 1980s, when screening ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC50 of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses ...
based inSunnyvale, CALIFORNIA (USA)
Olympia Diagnostics is an In Vitro Diagnostics (IVD) company focusing on development and commercialization of the most advanced breakthrough products for cancer diagnosis and prognosis. We developed a proprietary biomarker discovery platform to ...
A diagnostic test kit quantitatively measures the expression levels of a panel of prostate cancer risk-associated biomarkers in patient urine sample or biopsy tissue sample to distinguish high-risk and aggressive prostate cancer needing immediate ...
based inOxford, UNITED KINGDOM
Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth ...
based inKerrville, TEXAS (USA)
Vitanova Biomedical, Inc. (VNB) is a San Antonio, TX-based early stage biotechnology company developing patented (pending) technology licensed from the University of Texas at San Antonio. The company’s cancer treatment, Light-Activated Intracellular ...
Vitanova Biomedical’s Cancer Therapy Technology Platform is Called Light-Activated Intracellular Acidosis (LAIA). Vitanova Biomedical (VNB) has developed a proprietary energy-based technique to elicit cancer-specific intracellular acidosis. ...
based inSan Diego, CALIFORNIA (USA)
Decipher, a part of Veracyte, offers genomic tests for urologic cancers. Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with ...
Using Decipher genomic testing to determine where a patient is within the spectrum of risk empowers you in personalizing patient ...
based inBuford, GEORGIA (US) (USA)
Continuing To Do More To Save More Lives. Theragenics was founded in 1981 and quickly became a global leader in the manufacture of radioactive brachytherapy seeds for the treatment of localized prostate cancer. We began diversifying operations in ...
Brachytherapy seed placement is critical for prostate cancer outcomes. Cesium Blu (Cs-131) paired with the Sirius® MRI Marker gives you a clear picture of every implant for highly precise prostate cancer ...
based inFranklin, TENNESSEE (USA)
Created by urologists for urologists, UroTech is the best way to use advanced medical technology: Avoid significant capital expenditures: Purchasing just one of the advanced technologies now available - much less the five offered by UroTech - would ...
Cryoablation is emerging as an effective, minimally invasive treatment for localized prostate cancer. Cryoablation is revolutionizing localized prostate cancer treatment by ...
based inIrvine, CALIFORNIA (USA)
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and ...